Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes

A 22-year-old Japanese woman consulted an endocrinologist due to persistent galactorrhea for the past 10 months. She had hyperprolacinemia and had previously been diagnosed with type 2 diabetes mellitus based on her glycohemoglobin level of 11.6%. After two months, she was admitted to our hospital a...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshige, Tamami, Nakamura, Yui, Sasaki, Yuko, Kawano, Seiko, Ohki, Tsuyoshi, Tsuruta, Munehisa, Tokubuchi, Ichiro, Nakayama, Hitomi, Yamada, Kentaro, Ashida, Kenji, Tajiri, Yuji, Nomura, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875449/
https://www.ncbi.nlm.nih.gov/pubmed/31243214
http://dx.doi.org/10.2169/internalmedicine.2755-19
Descripción
Sumario:A 22-year-old Japanese woman consulted an endocrinologist due to persistent galactorrhea for the past 10 months. She had hyperprolacinemia and had previously been diagnosed with type 2 diabetes mellitus based on her glycohemoglobin level of 11.6%. After two months, she was admitted to our hospital and finally diagnosed with prolactinoma. For the treatment of prolactinoma, bromocriptine 2.5 mg/day was started. After seven days, her post-prandial blood glucose levels, homeostasis model assessment of insulin resistance and plasma C-peptide levels were significantly improved. These results indicate that traditional bromocriptine can be an effective therapeutic alternative in patients with prolactinoma complicated with type 2 diabetes.

Ejemplares similares